ARS Pharmaceuticals (SPRY) Return on Capital Employed (2021 - 2026)

ARS Pharmaceuticals has disclosed Return on Capital Employed across 6 years of filings, most recently posting 22.85% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 22.85%, down 1417.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 22.85% (down 1417.0% YoY), and the FY2025 annual result was 11.99%, down 1084.0% from the prior year.
• Return on Capital Employed came in at 22.85% for Q1 2026 at ARS Pharmaceuticals, down from 11.57% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 9.53% in Q3 2022 to a low of 31.06% in Q3 2025.
• The 5-year median for Return on Capital Employed is 8.69% (2025), against an average of 10.76%.
• Across the five-year window, Return on Capital Employed soared 3252 bps in 2022 and sank 3953 bps in 2023, its largest moves.
• ARS Pharmaceuticals' Return on Capital Employed stood at 13.11% in 2022, then surged by 63 bps to 4.79% in 2023, then jumped by 75 bps to 1.18% in 2024, then sank by 879 bps to 11.57% in 2025, then slumped by 98 bps to 22.85% in 2026.
• The last three Return on Capital Employed figures came in at 22.85% (Q1 2026), 11.57% (Q4 2025), and 31.06% (Q3 2025), per Business Quant data.